Literature DB >> 18768956

Cancer immunotherapy.

Steven A Rosenberg, Mark E Dudley, Nicholas P Restifo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18768956      PMCID： PMC6372305          DOI： 10.1056/NEJMc081511

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 2.  Cancer immunology.

Authors:  Olivera J Finn
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

3.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

4.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

5.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

Authors:  S A Rosenberg; J R Yannelli; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  J Natl Cancer Inst       Date:  1994-08-03       Impact factor: 13.506
  5 in total
  19 in total

1.  Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection.

Authors:  Emily C Bellavance; Frederick J Kohlhapp; Andrew Zloza; Jeremy A O'Sullivan; James McCracken; Michael C Jagoda; Andrew T Lacek; Mitchell C Posner; Jose A Guevara-Patino
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

2.  Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

Authors:  Håkan Norell; Telma Martins da Palma; Aaron Lesher; Navtej Kaur; Meenal Mehrotra; Osama S Naga; Natalie Spivey; Seye Olafimihan; Nitya G Chakraborty; Christina Voelkel-Johnson; Michael I Nishimura; Bijay Mukherji; Shikhar Mehrotra
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

3.  Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.

Authors:  Ali R Jazirehi; Dylan Arle
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

4.  Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.

Authors:  Kyle K Payne; Christine K Zoon; Wen Wan; Khin Marlar; Rebecca C Keim; Mehrab Nasiri Kenari; A Latif Kazim; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2013-10-25       Impact factor: 4.872

Review 5.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

6.  Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.

Authors:  Arvind Chhabra; Bijay Mukherji
Journal:  J Immunol       Date:  2013-08-09       Impact factor: 5.422

7.  Molecular insights for optimizing T cell receptor specificity against cancer.

Authors:  Michael Hebeisen; Susanne G Oberle; Danilo Presotto; Daniel E Speiser; Dietmar Zehn; Nathalie Rufer
Journal:  Front Immunol       Date:  2013-06-19       Impact factor: 7.561

8.  Defective HLA class I antigen processing machinery in cancer.

Authors:  Lei Cai; Theodoros Michelakos; Teppei Yamada; Song Fan; Xinhui Wang; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Cancer Immunol Immunother       Date:  2018-02-27       Impact factor: 6.968

9.  Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer.

Authors:  Jon G Quatromoni; Jarrod D Predina; Pratik Bhojnagarwala; Ryan P Judy; Jack Jiang; Elizabeth M De Jesus; Veena Kapoor; Guanjun Cheng; Olugbenga T Okusanya; Evgeniy Eruslanov; Sunil Singhal
Journal:  J Immunother       Date:  2014-06       Impact factor: 4.456

10.  Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.

Authors:  Meghaan P Walsh; Brynn Duncan; Shannon Larabee; Aviva Krauss; Jessica P E Davis; Yongzhi Cui; Su Young Kim; Martin Guimond; William Bachovchin; Terry J Fry
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.